Company profile
Johnson & Johnson
NYSE: JNJ · Healthcare · Drug Manufacturers - General
#9 of 1,422 Healthcare companies by revenue50th-percentile growth
EA Score
80B+FH 86DQ 76GM 57SS 100
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$96.4B
Rev growth YoY (TTM)
+7.9%
Net income (FY)
$26.8B
Employees
141,700
as of 2026-08-01
Market cap
$617.8B
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$94.2B$94.2B2025
Net income$26.8B$26.8B2025
Operating income$21.6B$21.6B2014
Total assets$199.2B$199.2B2025
Liabilities$117.7B$117.7B2025
Equity$81.5B$81.5B2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Innovative Medicine64%
MedTech36%
By geography
UNITED STATES57%
Europe23%
Asia-Pacific, Africa15%
Western Hemisphere, excluding U.S.5%
The read
What is Johnson & Johnson’s revenue?
Johnson & Johnson booked $94.2B in FY2025 revenue, growing 6.0% year over year — about the middle of the pack among Healthcare companies we track, at a 28.5% net margin.
Peers · Healthcare
Cardinal Health, Inc.84B+Elevance Health Inc.85ACentene Corp.81B+HCA Healthcare, Inc.78B+Eli Lilly and Company93AMerck & Co., Inc.84B+Neighbors
Middlesex →Key facts
CEOJoaquin Duato
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersNew Brunswick, NJ
ExchangeNYSE: JNJ
Employees141,700
IPO date1962-01-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.